Your browser doesn't support javascript.
loading
An Overview of Rickets in Children.
Chanchlani, Rahul; Nemer, Paul; Sinha, Rajiv; Nemer, Lena; Krishnappa, Vinod; Sochett, Etienne; Safadi, Fayez; Raina, Rupesh.
Afiliação
  • Chanchlani R; Division of Pediatric Nephrology, Department of Pediatrics, McMaster Children's Hospital, Hamilton, Ontario, Canada.
  • Nemer P; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada.
  • Sinha R; Akron Nephrology Associates/Cleveland Clinic Akron General, Akron, Ohio, USA.
  • Nemer L; Division of Pediatric Nephrology, Institute of Child Health, Kolkata, India.
  • Krishnappa V; Akron Nephrology Associates/Cleveland Clinic Akron General, Akron, Ohio, USA.
  • Sochett E; Akron Nephrology Associates/Cleveland Clinic Akron General, Akron, Ohio, USA.
  • Safadi F; Department of Public Health, Northeast Ohio Medical University, Rootstown, Ohio, USA.
  • Raina R; Division of Pediatrics Endocrinology, The Hospital for Sick Children, Toronto, Ontario, Canada.
Kidney Int Rep ; 5(7): 980-990, 2020 Jul.
Article em En | MEDLINE | ID: mdl-32647755
Rickets is a common bone disease worldwide that is associated with disturbances in calcium and phosphate homeostasis and can lead to short stature and joint deformities. Rickets can be diagnosed based on history and physical examination, radiological features, and biochemical tests. It can be classified into 2 major groups based on phosphate or calcium levels: phosphopenic and calcipenic. Knowledge of categorization of the type of rickets is essential for prompt diagnosis and proper management. Nutritional rickets is a preventable disease through adequate intake of vitamin D through both dietary and sunlight exposure. There are other subtypes of rickets, such as vitamin D-dependent type 1 rickets and vitamin D-dependent type 2 rickets (due to defects in vitamin D metabolism), renal rickets (due to poor kidney function), and hypophosphatemic rickets (vitamin D-resistant rickets secondary to renal phosphate wasting wherein fibroblast growth factor-23 (FGF-23) often plays a major role), which requires closer monitoring and supplementation with activated vitamin D with or without phosphate supplements. An important development has been the introduction of burosumab, a human monoclonal antibody to FGF-23, which is approved for the treatment of X-linked hypophosphatemia among children 1 year and older.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Kidney Int Rep Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Kidney Int Rep Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Canadá